ACHEMA Newsroom

Heidelberg Delivery Technologies: Medication without a needle

Heidelberg Delivery Technologies, short  „HeiDelTec“, develops a drug delivery technology for oral administration of peptides and proteins. Peptide and protein based pharmaceuticals are used to treat diabetes, cancer and various autoimmune diseases. Peptides and proteins cannot be administered orally as they are quickly decomposed in the stomach and/or cannot be retrieved in the intestines. Thus, they have to be injected. The HeiDelTec technology makes syringes dispensable.

No syringe

For patients, syringes mean injection pain, difficult administraion and social stigma. This often leads to an erroneous application or break-off of therapies. Bad compliance can have fatal consequences for patients and results in high costs for the health system due to secondary disorders. Oral administration thus brings advantages for patients and producers.

HeiDelTec's technology allows for oral administration of peptide or proteine based pharmaceuticals. Pept

Reaching the goal safely

With its liposomal matrix system HeiDelTec offers the possibility to administer peptide and protein pharmaceuticals orally in a solid shape and thus makes syringes dispensable. The technology is based on liposomes that are embedded in a matrix and processed to a solid dosage form. The liposomes can additionally be stabilised by tetrahedron lipides in order to carry the active ingredient safely through the stomach to the gut. The stabilisation protects both the liposomes and the embedded ingredient against decomposition in the stomach, the ingredient can then be resorbed undamaged in the small intestine. Resorption can be improved depending on the API by the targeted and mild application of bioenhancers. A special production process allows for high concentrations of the embedded API. In addition, the pharmaceuticals improves shelf-life and allows for a controlled single dosage of API.

Heidelberg Delivery Technologies GmbH, short „HeiDelTec“ was founded in 2017 and originates from the spin-off project PEPTORAL at the Institut für Pharmazie of Heidelberg University that has been funded by the EXIST Research Transfer Program.